Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tracy L Diamond

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trialChloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialAmy E Colson, Anthony M Mills, Moti N Ramgopal, et al.
ACS Medicinal Chemistry Letters|July 19, 2023
Discovery of [<sup>11</sup>C]MK-8056: A Selective PET Imaging Agent for the Study of mGluR<sub>2</sub> Negative Allosteric ModulatorsJames J Perkins, Paul McQuade, Christopher J Bungard, et al.
Cell|October 16, 2008
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replicationRenate König, Yingyao Zhou, Daniel Elleder, et al.
Plos Biology|August 26, 2025
MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosingIzzat T Raheem, Vinay Girijavallabhan, Kerry L Fillgrove, et al.
Science Translational Medicine|February 22, 2023
Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1Carl J Balibar, Daniel J Klein, Beata Zamlynny, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease InhibitorsChristopher J Bungard, Peter D Williams, Jurgen Schulz, et al.
ACS Chemical Biology|August 31, 2022
A Phenotypic Screen Identifies Potent DPP9 Inhibitors Capable of Killing HIV-1 Infected CellsKeith P Moore, Adam G Schwaid, Matthew Tudor, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding GroupChristopher J Bungard, Peter D Williams, Jeanine E Ballard, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trialChloe Orkin, Rosie Mngqibisa, Juan Diego Velez, et al.
Lancet (London, England)|February 7, 2026
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on bictegravir, emtricitabine, and tenofovir alafenamide: 48-week results of a phase 3, multicentre, randomised, controlled, double-blind, non-inferiority trialAmy E Colson, Anthony M Mills, Moti N Ramgopal, et al.
ACS Medicinal Chemistry Letters|July 19, 2023
Discovery of [<sup>11</sup>C]MK-8056: A Selective PET Imaging Agent for the Study of mGluR<sub>2</sub> Negative Allosteric ModulatorsJames J Perkins, Paul McQuade, Christopher J Bungard, et al.
Cell|October 16, 2008
Global analysis of host-pathogen interactions that regulate early-stage HIV-1 replicationRenate König, Yingyao Zhou, Daniel Elleder, et al.
Plos Biology|August 26, 2025
MK-8527 is a novel inhibitor of HIV-1 reverse transcriptase translocation with potential for extended-duration dosingIzzat T Raheem, Vinay Girijavallabhan, Kerry L Fillgrove, et al.
Science Translational Medicine|February 22, 2023
Potent targeted activator of cell kill molecules eliminate cells expressing HIV-1Carl J Balibar, Daniel J Klein, Beata Zamlynny, et al.
ACS Medicinal Chemistry Letters|December 21, 2017
Design and Synthesis of Piperazine Sulfonamide Cores Leading to Highly Potent HIV-1 Protease InhibitorsChristopher J Bungard, Peter D Williams, Jurgen Schulz, et al.
ACS Chemical Biology|August 31, 2022
A Phenotypic Screen Identifies Potent DPP9 Inhibitors Capable of Killing HIV-1 Infected CellsKeith P Moore, Adam G Schwaid, Matthew Tudor, et al.
ACS Medicinal Chemistry Letters|July 21, 2016
Discovery of MK-8718, an HIV Protease Inhibitor Containing a Novel Morpholine Aspartate Binding GroupChristopher J Bungard, Peter D Williams, Jeanine E Ballard, et al.
Pageof 3